Click here to see the meta data of this asset.

Opioid addiction treatment: References

Amato, L., Davoli, M., Ferri, M., Gowing, L. & Perucci, C.A. (2004). Effectiveness of interventions on opiate withdrawal treatment: An overview of systematic reviews. Drug and Alcohol Dependence73 (3), 219–226.

Auriacombe, M., Fatséas, M., Dubernet, J., Daulouède, J.P. & Tignol, J. (2004). French field experience with buprenorphine. American Journal of Addiction, 13 (Suppl. 1), S17–S28.

Blondell, R.D., Smith, S.J., Servoss, T.J., DeVaul, S.K. & Simons, R.L. (2007). Buprenorphine and methadone: A comparison of patient completion rates during inpatient detoxification. Journal of Addictive Diseases, 26 (2), 3–11.

Borron, S.W., Monier, C., Risède, P. & Baud, F.J. (2002). Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Human & Experimental Toxicology, 21 (11), 599–605.

Brigham, G.S., Amass, L., Winhusen, T., Harrer, J.M. & Pelt, A. (2007). Using buprenorphine short-term taper to facilitate early treatment engagement. Journal of Substance Abuse Treatment, 32 (4), 349–356.

Caldiero, R.M. Parran, T.V. Jr, Adelman, C.L. & Piche, B. (2006). Inpatient initiation of buprenorphine maintenance vs. detoxification: Can retention of opioid-dependent patients in outpatient counseling be improved? American Journal of Addiction, 15 (1), 1–7.

Chelminski, P.R., Ives, T.J., Felix, K.M., Prakken, S.D., Miller, T.M., Perhac, J.S. et al. (2005). A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic noncancer pain and a high burden of psychiatric comorbidity. BMC Health Services Research, 5 (1), 3.

Comer, S.D., Sullivan, M.A., Yu, E., Rothenberg, J.L., Kleber, H.D., Kampman, K. et al. (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Archives of General Psychiatry, 63, 210–218.

Currie, S.R., Hodgins, D.C., Crabtree, A., Jacobi, J. & Armstrong, S. (2003). Outcome from integrated pain management treatment for recovering substance abusers. Journal of Pain, 4 (2), 91–100.

Gowing, L., Ali, R. & White, J. (2002). Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, 2: CD002025.

Jamison, R.N., Ross, E.L., Michna, E., Chen, L.Q., Holcomb, C. & Wasan, A.D. (2010). Substance misuse treatment for high-risk chronic pain patients on opioid therapy: A randomized trial. Pain, 3 (22), 390–400.

Kahan, M., Srivastava, A., Ordean, A. & Cirone, S. (2011). Buprenorphine: A new treatment for opioid dependence in primary care. Canadian Family Physician, 57 (3), 281–290.

Kirchmayer, U., Davoli, M., Verster, A.D., Amato, L., Ferri, A. & Perucci, C.A. (2002). A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction, 97 (10), 1241–1249.

Lintzeris, N., Muhleisen, P. & Ritter, A. (2001). Clinical Guidelines: Buprenorphine Treatment of Heroin Dependence. Canberra, Australia: National Expert Advisory Committee on Illicit Drugs.

Madden, M.E. & Shapiro, S.L. (2011). The methadone epidemic: Methadone-related deaths on the rise in Vermont. American Journal of Forensic Medicine and Pathology, 32 (2), 131–135. doi: 10.1097/PAF.0b013e3181e8af3d.

Manchikanti, L., Cash, K.A., Damron, K.S., Manchukonda, R., Pampati, V. & McManus, C.D. (2006a). Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician, 9 (3), 215–225.

Manchikanti, L., Manchukonda, R., Damron, K.S., Brandon, D., McManus, C.D. & Cash, K. (2006b). Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician, 9 (1), 57–60.

Wiedemer, N.L., Harden, P.S., Arndt, I.O. & Gallagher, R.M. (2007). The opioid renewal clinic: A primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Medicine, 8 (7), 573–584.